Atypical thrombotic and septic complications of totally implantable venous access devices in patients with cystic fibrosis
Atypical thrombotic and septic complications of totally implantable venous access devices in patients with cystic fibrosis
复制标题
囊性纤维化患者完全植入式静脉通路装置的非典型血栓和脓毒症并发症
作者：
J. Sola;M. Stone;B. Wise;P. Colombani
血管通路系统在囊性纤维化（CF）患者中的使用被广泛接受，其总体并发症和维护成本低于经皮硅橡胶导管。我们报告了我们6年的经验，22输液港在15个CF患者。我们的患者平均每根导管留置导管539天（范围142，224天）。这些输液港用于家庭抗生素治疗、血液采样和全胃肠外营养。总体并发症发生率相对较低，每1，483个导管日发生1例。感染并发症极为罕见，发生率为1/5，929导管日。机械并发症的发生率为1/1，976导管日。然而，上级腔静脉综合征或深静脉血栓形成与22根导管中的3根（13.6%）相关。由于主要血栓形成事件的高发生率以及伴随的肺栓塞风险，所有使用输液港且无肝病或出血问题证据的CF患者均接受阿司匹林预防治疗。© 1992 Wiley利斯公司
The use of vascular access systems in patients with cystic fibrosis (CF) is well accepted, with lower overall complications and maintenance costs than percutaneous silastic catheters. We report our 6 year experience with 22 infusaports in 15 CF patients. Our patients had indwelling catheters for an average of 539 days per catheter (range, 142,224 days). These infusaports were used for home antibiotic therapy, blood sampling, and total parenteral nutrition. The overall complication rate was relatively low, 1 in every 1,483 catheter days. Infectious complications were extremely infrequent at a rate of 1 in 5,929 catheter days. The rate of mechanical complications was 1 in 1,976 catheter days. However, superior vena caval syndrome or deep venous thrombosis was associated with 3 of 22 catheters (13.6%). Due to this high incidence of major thrombotic events with the attendant risk of pulmonary embolism, all patients with CF using infusaports and without evidence of liver disease or bleeding problems receive aspirin prophylaxis. © 1992 Wiley‐Liss, Inc.
囊性纤维化的完全植入式血管通路装置：58 名患者的四年经验。
DOI：
10.1016/s0022-3476(05)82450-3
发表时间：
1990
期刊：
The Journal of pediatrics
影响因子：
--
作者：
Morris,JB;Occhionero,ME;Gauderer,MW;Stern,RC;Doershuk,CF
通讯作者：
Doershuk,CF